Skip to main content

Table 1 Clinicopathological characteristics of all the patients (n = 1511)

From: Development and validation of a prognostic nomogram for predicting early recurrence after curative resection of stage II/III gastric cancer

Variables aNomogram develop set (n = 1057)External validation set (n = 454)
Early recurrenceP valueEarly recurrenceP value
YesNoYesNo
(n = 216)(n = 841)(n = 95)(n = 359)
Age (years)57.28 ± 11.7055.31 ± 10.750.01856.35 ± 11.9855.74 ± 10.200.618
Sex  0.741  0.770
 Female75 (7.10%)282 (26.88%) 33 (7.27%)119 (26.21%) 
 Male141 (13.34%)559 (52.89%) 62 (13.66%)240 (52.86%) 
Body mass index (kg/m2)21.14 ± 2.9221.82 ± 2.900.00221.23 ± 2.8922.00 ± 2.970.025
Any comorbidities  0.208  0.923
 No158 (14.95%)578 (54.68%) 67 (14.76%)255 (56.17%) 
 Yes58 (5.49%)263 (24.88%) 28 (6.17%)104 (22.91%) 
ASA score  0.097  0.770
 129 (2.74%)129 (12.20%) 17 (3.74%)70 (15.42%) 
 2152 (14.38%)619 (58.56%) 66 (14.54%)247 (54.41%) 
 335 (3.31%)89 (8.42%) 11 (2.42%)41 (9.03%) 
 40 (0%)4 (0.38%) 1 (0.22%)1 (0.22%) 
Hemoglobin (g/L)112.87 ± 26.06117.61 ± 25.070.014114.61 ± 27.02119.03 ± 25.020.132
Albumin level (g/L)37.27 ± 5.1438.08 ± 4.580.02437.74 ± 4.7437.95 ± 4.400.684
Lymphocyte count (×109/L)1.62 ± 0.611.77 ± 0.660.0021.66 ± 0.671.76 ± 0.600.153
Prognostic nutritional index45.35 ± 6.5346.94 ± 6.070.00146.01 ± 6.3946.73 ± 5.660.286
Tumor diameter (cm)5.26 ± 2.254.48 ± 2.00< 0.0015.10 ± 2.184.52 ± 2.000.014
Tumor location  < 0.001  0.002
 Upper27 (2.55%)74 (7.00%) 12 (12.64%)32 (7.05%) 
 Middle60 (5.68%)185 (17.50%) 30 (6.61%)81 (17.84%) 
 Lower112 (10.60%)561 (53.07%) 43 (9.47%)233 (51.32%) 
 Mixed17 (1.61%)21 (1.99%) 10 (2.20%)13 (2.86%) 
Gastrectomy extent  < 0.001  < 0.001
 Sub-total124 (11.73%)642 (60.74%) 53 (11.67%)268 (59.03%) 
 Total92 (8.70%)199 (18.83%) 42 (9.25%)91 (20.04%) 
Pathological type  0.131  0.541
 Differentiated15(1.42%)87 (8.23%) 9 (1.98%)42 (9.25%) 
 Undifferentiated201 (19.02%)754 (71.33%) 86 (18.94%)317 (69.82%) 
Positive lymph node ratio0.46 ± 0.290.23 ± 0.24< 0.0010.43 ± 0.310.23 ± 0.24< 0.001
Adjuvant
chemotherapy
  < 0.001  < 0.001
 ≥ 6 cycles45 (4.26%)286 (27.06%) 15 (3.30%)123 (27.09%) 
 <6 cycles171 (16.18%)555 (52.51%) 80 (17.62%)236 (51.98%) 
Peri-operative blood transfusion  < 0.001  0.025
 No142 (13.43%)670 (63.39%) 66 (14.54%)288 (63.44%) 
 Yes74 (7.00%)171 (16.18%) 29 (6.39%)71 (15.64%) 
Post-operative infection complications  < 0.001  0.660
 No189 (17.88%)798 (75.50%) 88 (19.33%)337 (74.23%) 
 Yes27 (2.55%)43 (4.07%) 7 (1.54%)22 (4.85%) 
pT stage  < 0.001  0.226
 T11 (0.09%)19 (1.80%) 1 (0.22%)7 (1.54%) 
 T25 (0.47%)89 (8.42%) 4 (0.88%)38 (8.37%) 
 T312 (1.14%)70 (6.62%) 6 (1.32%)26 (5.73%) 
 T4198 (18.73%)663 (62.72%) 84 (18.50%)288 (63.44%) 
pN stage  < 0.001  < 0.001
 N012 (1.14%)203 (19.21%) 11 (2.42%)96 (21.15%) 
 N128 (2.65%)178 (16.84%) 13 (2.86%)71 (15.64%) 
 N236 (3.41%)229 (21.67%) 20 (4.41%)94 (20.70%) 
 N3140 (13.25%)231 (21.85%) 51 (11.23%)98 (21.59%) 
pTNM stage  < 0.001  < 0.001
 II14 (1.32%)294 (27.81%) 14 (3.08%)137 (30.18%) 
 III202 (19.11%)547 (51.75%) 81 (17.84%)222 (48.90%) 
  1. aContinuous were present as mean ± SD and or categorical data were presented as n